Abstract:Importance: The COVID-19 pandemic led to the use of lung transplant as a lifesaving therapy for patients with irreversible lung injury. Limited information is currently available regarding the outcomes associated with this treatment modality. Objective: To describe the outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Design, setting, and participants: In this cohort study, lung transplant recipient and donor characteristics and outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis were extracted from the US United Network for Organ Sharing database from March 2020 to August 2022 with a median (IQR) follow-up period of 186 (64-359) days in the acute respiratory distress syndrome group and 181 (40-350) days in the pulmonary fibrosis group. Overall survival was calculated using the Kaplan-Meier method. Cox proportional regression models were used to examine the association of certain variables with overall survival. Exposures: Lung transplant following COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Main outcomes and measures: Overall survival and graft failure rates. Results: Among 385 included patients undergoing lung transplant, 195 had COVID-19-related acute respiratory distress syndrome (142 male [72.8%]; median [IQR] age, 46 [38-54] years; median [IQR] allocation score, 88.3 [80.5-91.1]) and 190 had COVID-19-related pulmonary fibrosis (150 male [78.9%]; median [IQR] age, 54 [45-62]; median [IQR] allocation score, 78.5 [47.7-88.3]). There were 16 instances of acute rejection (8.7%) in the acute respiratory distress syndrome group and 15 (8.6%) in the pulmonary fibrosis group. The 1-, 6-, and 12- month overall survival rates were 0.99 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.91-0.98), and 0.88 (95% CI, 0.80-0.94) for the acute respiratory distress syndrome cohort and 0.96 (95% CI, 0.92-0.98), 0.92 (95% CI, 0.86-0.96), and 0.84 (95% CI, 0.74-0.90) for the pulmonary fibrosis cohort. Freedom from graft failure rates were 0.98 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.90-0.97), and 0.88 (95% CI, 0.79-0.93) in the 1-, 6-, and 12-month follow-up periods in the acute respiratory distress cohort and 0.96 (95% CI, 0.92-0.98), 0.93 (95% CI, 0.87-0.96), and 0.85 (95% CI, 0.74-0.91) in the pulmonary fibrosis cohort, respectively. Receiving a graft from a donor with a heavy and prolonged history of smoking was associated with worse overall survival in the acute respiratory distress syndrome cohort, whereas the characteristics associated with worse overall survival in the pulmonary fibrosis cohort included female recipient, male donor, and high recipient body mass index. Conclusions and relevance: In this study, outcomes following lung transplant were similar in patients with irreversible respiratory failure due to COVID-19 and those with other pretransplant etiologies.

Impact of COVID‐19 on long‐term lung function in lung transplant recipients: A single‐center retrospective cohort study

LUNG TRANSPLANTATION DURING THE OUTBREAK OF CORONAVIRUS DISEASE 2019: EARLY EXPERIENCE FROM CHINA

Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Impact of the COVID-19 pandemic on lung transplant patients and on a cohort of patients with rare lung disease: a single-center study

Outcomes Following Lung Transplant for COVID-19-Related Complications in the US

Clinical characteristics and prognosis of SARS-CoV-2 infection in lung transplant recipients

Clinical outcomes for COVID-19 in lung transplant recipients (LTRs): an insight from the early Omicron wave

Impact of Coronavirus Disease 2019 on Pulmonary Function in Early Convalescence Phase

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

A Single-center Experience With >200 Lung Transplant Recipients With COVID-19 Infection

Clinical characteristics and outcomes of lung transplantation in patients with severe COVID-19 infection: A systematic review and meta-analysis

Lung Transplant Recipients and COVID-19: Report of Two Cases

SARS-CoV-2 and lung transplantation. What do we know?

A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19

Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge

COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases

COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients

Long-term COVID-19 effects on pulmonary function, exercise capacity, and health status

Persistent defect in SARS-CoV-2 humoral and cellular immunity in lung transplant recipients

Long‐term outcomes after COVID‐19 infection in transplant recipients

Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up